Our Story
ProGenis Pharmaceuticals is a leading RNA biotechnology company, founded in Perth, Western Australia, in 2022. We are dedicated to developing next-generation, precision RNA medicines for the treatment of acquired and inherited rare diseases.
Co-founded by renowned experts Professor Marvin Caruthers and Professor Rakesh Veedu, our team is driven by a shared commitment to improving the health and wellbeing of individuals through groundbreaking therapeutics.
We are driven by innovation
We are dedicated to developing breakthrough, disease-modifying therapeutics that are safer, more effective, and accessible, offering new hope to patients suffering from chronic and debilitating conditions.
Safe
No or low off-target toxicity
Effective
Precisely targeting the gene hallmark
Accessible
Affordable costs for all patients
Senior Leadership
Our senior leadership and advisory board are seasoned experts in biotechnology, medicine, and business, providing strategic leadership to drive ProGenis Pharmaceuticals’ mission of developing innovative RNA therapeutics.
Prof. Marvin H. Caruthers
Co-Founder & Director Board Member
Prof. Rakesh N. Veedu
Co-Founder & Director Board Member
David Schwartz
Director Board Member
Advisory Board
Vinod Vathipadiekal
Chief Scientific Officer
Prof. Bu Yeap
Clinical Advisor for Metabolic Diseases
Prof. Girish Dwivedi
Clinical Advisor for Cardiovascular Diseases
Join our team!
Be part of a team committed to transforming RNA therapeutics and advancing treatments for rare diseases. We’re looking for passionate individuals to make a real impact.
